Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Neurooncol ; 130(1): 141-148, 2016 10.
Article in English | MEDLINE | ID: mdl-27438082

ABSTRACT

Cerebral radiation necrosis (CRN) is a toxicity of radiation therapy that can result in significant, potentially life-threatening neurologic deficits. Treatment for CRN has included surgical resection, corticosteroids, hyperbaric oxygen therapy (HBOT), and bevacizumab, but no consensus approach has been identified. We reviewed the available literature to evaluate efficacy of treatment approaches. Using methods specified in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines when possible, we conducted searches of Ovid MEDLINE, Embase and Pubmed to identify studies reporting on outcomes for children (≤21 years old) with CRN. Eligible studies from 1990 to 2014 describing central nervous system (CNS) radiation necrosis with details of both treatment and outcomes were included. Eleven studies meeting criteria were identified. Of the nine studies with total patient denominators, 37 of 806 patients developed CRN (incidence = 4.6 %). Patients received treatment courses of steroids alone (n = 13), steroids with bevacizumab (n = 11) or HBOT (n = 12). Patients who failed to respond to steroids were more likely to be older than steroid-responsive patients (p = 0.009). With the exception of steroid-related adverse events, there was only one report of an adverse event (brainstem stroke) potentially attributable to intervention (bevacizumab). Those who received proton beam RT were both younger (p = 0.001) and had a shorter time to development of CRN (p = 0.079). The most common treatment following steroid initiation was addition of bevacizumab or HBOT, with good success and minimal toxicity. However, randomized controlled trials are needed to establish a definitive treatment algorithm that can be applied to children affected by CRN.


Subject(s)
Cerebral Cortex/pathology , Necrosis/etiology , Necrosis/therapy , Pediatrics , Radiotherapy/adverse effects , Bevacizumab/therapeutic use , Brain Neoplasms/radiotherapy , Databases, Bibliographic/statistics & numerical data , Humans , Steroids/therapeutic use
2.
J Intellect Disabil Res ; 60(3): 282-93, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26805654

ABSTRACT

BACKGROUND: This study examined social functioning and facial expression recognition (FER) in children with neurofibromatosis type 1 (NF1) compared to typically developing peers. Specifically, the current research aimed to identify hypothesised relationships between neurocognitive ability, FER and social functioning. METHOD: Children, ages 8 to 16, with NF1 (n = 23) and typically developing peers (n = 23) were recruited during regularly scheduled clinic visits and through advertisements on an institutional clinical trials website, respectively. Participants completed a measure of FER, an abbreviated intelligence test and questionnaires regarding their quality of life and behavioural functioning. Parents were also asked to complete questionnaires regarding the social-emotional and cognitive functioning of their child. RESULTS: As expected, there were significant differences between children with NF1 and typically developing peers across domains of social functioning and FER. Within the sample of children with NF1, there were no significant associations observed between cognitive measures, social functioning and facial recognition skills. CONCLUSION: Children with NF1 exhibited high rates of social impairment and weak FER skills compared to controls. The absence of associations between FER with cognitive and social variables, however, suggests something unique about this skill in children with NF1. Theoretical comparisons are made to children with autism spectrum disorders, as this condition may serve as a potentially useful model in better understanding FER in children with NF1.


Subject(s)
Cognition Disorders/physiopathology , Facial Expression , Facial Recognition/physiology , Neurofibromatosis 1/physiopathology , Social Skills , Adolescent , Child , Cognition Disorders/etiology , Female , Humans , Male , Neurofibromatosis 1/complications
3.
Pediatr Pulmonol ; 31(6): 443-50, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11389577

ABSTRACT

There is a growing population of adults with cystic fibrosis (CF) and a need for development of adult CF programs. Recommendations for transfer of patients to an adult program include a transition program. Our goal was to assess the current status of transition programs in US CF centers. In addition, we sought to determine the problems related to the transfer of patients to adult programs as perceived by CF center program directors. A survey was sent in 1998 to 110 pediatric and 44 adult program directors at CF centers approved by the Cystic Fibrosis Foundation (CFF), with a response rate of 65.5% and 72.7%, respectively: 22.2% of pediatric centers reported having a non-CFF-approved adult program, and 38.9% had no specific adult program. About one fifth of pediatric centers cited lack of an adult CF physician as an impediment to establishing an adult program. Age (82% of programs; mean, 18.5 years), but not marriage (17.1%) or pregnancy (24.8%), was used as a criterion for transfer. Criteria precluding transfer included patient/family resistance (51.4%), disease severity (50.5%), and developmental delay (46.7%). The concept of transfer is introduced to the patient and family at the time of diagnosis in a minority (14%) of programs. Over one half of the patients did not meet the adult team until the time of transfer. Pediatricians reported higher perceived parent, patient, pediatric staff, and adult staff concerns about transition issues than did adult program directors. We conclude that there is a lack of standardized programs for transfer of CF patients from a pediatric to an adult care setting, and that there are differences between pediatric and adult program directors' perceptions of concerns that CF patients, their families, and the medical teams have about transfer. These differences may impede the successful transition of patients into an adult program.


Subject(s)
Ambulatory Care Facilities , Attitude of Health Personnel , Continuity of Patient Care , Cystic Fibrosis/therapy , Patient Transfer , Adolescent , Adult , Age Factors , Child , Family Health , Female , Health Care Surveys , Humans , Male , Pediatrics , Referral and Consultation
4.
Chest ; 119(4): 1079-84, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11296173

ABSTRACT

STUDY OBJECTIVES: The purpose of this study is to assess the psychological profiles of adult patients with cystic fibrosis (CF) and to investigate predictors of patients' psychological status. PATIENTS AND METHODS: Thirty-four adults with CF completed a battery of psychological testing including the Minnesota Multiphasic Personality Inventory-2, Beck Depression Inventory, and State-Trait Anxiety inventory. These were compared to health status data, including pulmonary function testing and nutritional status measures. RESULTS: As a group, adults with CF did not demonstrate significant levels of depression, anxiety, or other psychopathology. Results were not affected by age, sex, or severity of disease. Male gender predicted higher scores for depression and anxiety, and better lung functioning predicted less anxiety. Having a higher level of psychosocial support emerged as a strong predictor of better psychological functioning. CONCLUSIONS: Overall, adults with CF report relatively healthy psychological functioning. Better lung function and a strong social support system predicted better psychological functioning, which may have implications for clinical intervention.


Subject(s)
Cystic Fibrosis/psychology , Adolescent , Adult , Anxiety/complications , Anxiety/diagnosis , Attitude to Health , Cystic Fibrosis/physiopathology , Depression/complications , Depression/diagnosis , Female , Forced Expiratory Volume , Health Status , Humans , Internal-External Control , Male , Middle Aged , Personality Assessment , Psychological Tests , Social Support , Vital Capacity
5.
Neuropsychopharmacology ; 17(6): 391-401, 1997 Dec.
Article in English | MEDLINE | ID: mdl-9397427

ABSTRACT

This study reports the effects of intravenous dextroamphetamine on cerebral glucose metabolism assayed by positron emission tomography (PET) and [fluorine-18]fluorodeoxyglucose (FDG) in 13 healthy adults during the performance of a continuous visual attention task. Two FDG PET scans were performed within a single experimental session. The first scan was preceded by the injection of placebo and the second scan by the injection of 0.15 mg/kg dextroamphetamine. Global and normalized regional glucose metabolic rates (rCMRglc) were examined as a function of pharmacological challenge and subjective experience. Subcortical, limbic, frontal, and cerebellar rCMRglc significantly increased after dextroamphetamine, whereas rCMRglc of the temporal cortex significantly decreased. Physiological and self-report measures of subjective states showed the expected alterations. These rCMRglc changes reflect both the direct pharmacological effect of dextroamphetamine on monoaminergic neurotransmitter systems as well as enhancement of the activation of the neural network mediating the performance of the continuous attention task.


Subject(s)
Brain Chemistry/drug effects , Central Nervous System Stimulants/pharmacology , Dextroamphetamine/pharmacology , Glucose/metabolism , Adult , Affect/drug effects , Arousal/drug effects , Attention/physiology , Blood Pressure/drug effects , Central Nervous System Stimulants/administration & dosage , Dextroamphetamine/administration & dosage , Female , Fluorodeoxyglucose F18 , Heart Rate/drug effects , Humans , Injections, Intravenous , Male , Psychomotor Performance/drug effects , Tomography, Emission-Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...